Yokogawa Survey Reveals Significant Impact of Industrial Autonomy on Environmental Sustainability
27.1.2022 06:05:00 EET | Business Wire | Press release
Yokogawa Electric Corporation (TOKYO: 6841) reveals today the results of its latest survey* to gain further insights into the current and future state of industrial autonomy in process manufacturing. The survey highlights that the number of manufacturers moving forward with industrial autonomy is clearly increasing, and that there is a high awareness of the expected benefits on environmental sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220127005054/en/
The global survey was conducted in seven markets (China, Germany, India, Japan, Saudi Arabia, SE Asia and the US) amongst 534 respondents from 390 companies in the chemical & petrochemical, life sciences, oil & gas, power generation, and renewable energy industry sectors.
Key insights
Regarding environmental sustainability, 45% of the respondents anticipate that industrial autonomy will have a significant impact and another 36% expect a moderate impact in the areas of dynamic energy optimization, water management, and emissions reduction. In contrast, only 6% expect industrial autonomy to have no impact at all on environmental sustainability.
The implementation of industrial autonomy projects is starting to gather pace, with 51% of the respondents surveyed now scaling deployment across multiple facilities and business functions and another 19% reporting they have deployed in at least one facility or business function.
While productivity improvements in production and manufacturing processes are expected to deliver the highest return on investment (ROI) in digital transformation over the next three years – with 31% ranking this area first and a further 20% ranking it second – health, safety and environment is emerging as a key area of ROI, with 26% ranking it first (13%) or second (13%).
With the ongoing COVID-19 pandemic, increasing remote operations capabilities represents a key factor in industrial autonomy. The survey reveals that one-third (33%) of manufacturers have deployed remote operations in single sites and 31% have implemented across multi-sites in connection to industrial autonomy.
C-level executives play a key role in plant-level autonomous planning, with the survey respondents saying that the Chief Executive Officer (38%), Chief Technical Officer (34%), and Chief Information Officer (31%) are the primary final decision-makers. These decision-makers are supported by senior level technical professionals, with 43% saying the Chief Digital Officer has significant influence on plant level autonomy decisions.
“It is gratifying to see from our latest survey that environmental sustainability is emerging as an area in which the shift from industrial automation to industrial autonomy, which we call IA2IA, is expected to make a significant positive impact,” explained Tsuyoshi Abe, senior vice president and head of the Marketing Headquarters at Yokogawa Electric. “Overall, however, our survey also indicates that one of the biggest challenges in implementing industrial autonomy is the lack of a clear roadmap, with almost half seeing it as their most significant challenge. This underlines the importance of a defined roadmap to industrial autonomy and finding the right partner to develop it.”
The survey report can be downloaded from the following website:
https://www.yokogawa.com/ia2ia/
* The "Global End-user Survey on the Implementation of Industrial Autonomy" was conducted on behalf of Yokogawa by research company Omdia in September 2021 among 534 respondents from 390 companies across seven global markets: China, Germany, India, Japan, Saudi Arabia, SE Asia, and the US. Respondents comprised manufacturers/end-users, OEMs, and systems integrators in the chemical & petrochemical, life sciences, upstream and mid-stream oil & gas, refining, power generation, and renewable energy power generation industry sectors. The survey respondents were in IT management, operations/project/plant management, and corporate management.
About Yokogawa
Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.
Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,500 employees in a global network of 119 companies spanning 61 countries.
For more information, visit www.yokogawa.com
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005054/en/
Contact information
Media inquiries:
PR Section,
Integrated Communications Center
Yokogawa Electric Corporation
E-mail: Yokogawa-pr@cs.jp.yokogawa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
